1	Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic
2	epidemiological study
3	
4	
5	Barun Mathema <sup>1,a</sup> , Liang Chen <sup>2,3,a</sup> , Kar Fai Chow <sup>4</sup> , Yanan Zhao <sup>2,3</sup> , Michael C Zody <sup>5</sup> , Jose R
6	Mediavilla <sup>2</sup> , Marcus H Cunningham <sup>2</sup> , Kaelea Composto <sup>2</sup> , Annie Lee <sup>2</sup> , Dayna M Oschwald <sup>5</sup> ,
7	Soren Germer <sup>5</sup> , Samantha Fennessey <sup>5</sup> , Kishan Patel <sup>4</sup> , David Wilson <sup>6</sup> , Ann Cassell <sup>6</sup> , Lauren
8	Pascual <sup>7</sup> , Andrew Ip <sup>7</sup> , André Corvelo <sup>5</sup> , Sophia Dar <sup>4</sup> , Yael Kramer <sup>4</sup> , Tom Maniatis <sup>5</sup> , David S
9	Perlin <sup>2,3</sup> , Barry N Kreiswirth <sup>2*</sup>
10	
11	1. Mailman School of Public Health, Columbia University Irving Medical Center, New York,
12	NY, USA
13	2. Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, USA
14	3. Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
15	4. Hackensack Meridian Health Biorepository, Hackensack, NJ. USA
16	5. New York Genome Center, New York, NY, USA
17	6. Hackensack Meridian Health BI Analytics, Edison, NJ, USA
18	7. John Theurer Cancer Center, Outcomes Division, Hackensack University Medical
19	Center, Hackensack, NJ, USA.
20	
21	<sup>a</sup> Barun Mathema and Liang Chen contributed equally to this article. The order of co-first authors
22	was determined by discussion and mutual agreement between the two co-first authors.
23	
24	*Correspondence to: Dr. Barry N Kreiswirth, Barry.Kreiswirth@hmh-cdi.org
25	
26	Running title: Post-vaccination COVID-19 in New Jersey

## 27 ABSTRACT

28 Emergence of SARS-CoV-2 with high transmission and immune evasion potential, the so-called 29 Variants of Concern (VOC), is a major concern. We describe the early genomic epidemiology of 30 SARS-CoV-2 recovered from vaccinated healthcare professionals (HCP). Our post-vaccination 31 COVID-19 symptoms-based surveillance program among HCPs in a 17-hospital network, 32 identified all vaccinated HCP who tested positive for COVID-19 after routine screening or after 33 self-reporting. From 01/01/2021 to 04/30/2021, 23,687 HCP received either mRNA-1273 or 34 BNT162b2 mRNA vaccine. All available post-vaccination SARS-CoV-2 samples and a random 35 collection from non-vaccinated patients during the similar timeframe were subjected to VOC 36 screening and whole genome sequencing (WGS). 62% (23,697/37,500) of HCPs received at 37 least one vaccine dose, with 95% (22,458) fully vaccinated. We detected 138 (0.58%, 38 138/23,697) COVID-19 cases, 105 among partially vaccinated and 33 (0.15%, 33/22,458) 39 among fully vaccinated. Five partially vaccinated required hospitalization, four with supplemental 40 oxygen. VOC screening from 16 fully vaccinated HCPs identified 6 (38%) harboring N501Y and 41 1 (6%) with E484K polymorphisms; concurrent non-vaccinated samples was 37% (523/1404) 42 and 20% (284/1394), respectively. There was an upward trend from January to April for 43 E484K/Q (3% to 26%) and N501Y (1% to 49%). WGS analysis from vaccinated and non-44 vaccinated individuals indicated highly congruent phylogenies. We did not detect an increased 45 frequency of any RBD/NTD polymorphism between groups (P>0.05). Our results support robust 46 protection by vaccination, particularly among recipients of both doses. Despite VOCs 47 accounting for over 40% of SARS-CoV-2 from fully vaccinated individuals, the genomic diversity 48 appears to proportionally represent those among non-vaccinated populations.

49

50

#### 52 **IMPORTANCE**

53 A number of highly effective vaccines have been developed and deployed to combat the 54 COVID-19 pandemic. The emergence and epidemiological dominance of SARS-CoV-2 mutants, 55 with high transmission potential and immune evasion properties, the so-called Variants of 56 Concern (VOC), continues to be a major concern. Whether these VOCs alter the efficacy of the 57 administered vaccines is of great concern, and a critical guestion to study. We describe the 58 initial genomic epidemiology of SARS-CoV-2 recovered from vaccinated healthcare 59 professionals and probe specifically for VOC enrichment. Our findings support the high-level of 60 protection provided by full vaccination despite a steep increase in the prevalence of 61 polymorphisms associated with increased transmission potential (N501Y) and immune evasion 62 (E484K) in the non-vaccinated population. Thus, we do not find evidence of VOC enrichment 63 among vaccinated groups. Overall, the genomic diversity of SARS-CoV-2 recovered post-64 vaccination appears to proportionally represent the observed viral diversity within the 65 community.

66

Key words: COVID-19, SARS-CoV-2, Variants of Concern, vaccine, breakthrough, spike
protein

69

## 71 INTRODUCTION

Since the beginning of the pandemic in 2020, SARS-CoV-2 has infected and spread within an immunologically naïve global population (1, 2). With the application of convalescent plasma and therapeutic antibody treatment, along with highly effective vaccines, the virus is now starting to experience the immune pressure that will ultimately shape its evolutionary trajectory (3). Recent evidence indicates that SARS-CoV-2 can mutate and evade immunity and challenge the efficacy of emerging vaccines and intrinsic and extrinsic antibodies (i.e., natural by infection and antibody therapeutics) (3, 4).

79 The reports of mutants, known as Variants of Concerns (VOCs) that exhibit increased 80 transmission or immune evasion, or both, have been reported in different global regions and 81 predominant lineages have been genotyped (5). Of note, three VOCs, B.1.1.7 (recently named 82 Alpha) (6), B.1.351 (Beta) (7), and P.1 (Gamma) (8) containing prominent mutations in the spike 83 protein, emerged in the UK, South Africa and Brazil, respectively, and more recently, B.1.617.2 84 (Delta) (9) emerged in India and has spread globally. The mapping of specific mutations in the 85 spike protein has revealed strong evidence of convergent evolution, and particularly the E484K 86 polymorphism, which is able to evade certain monoclonal therapy and it is less responsive to 87 neutralizing antibodies from recovered patients. This mutant shows reduced response to 88 convalescent plasma and reported reinfections and it has been identified in discrete lineages in 89 different geographic locations and associated with variant clones with increased incidence (4). 90 The impact of these antibody escape mutants harboring VOCs on driving community incidence 91 and whether they alter the efficacy of the administered vaccines is of great concern.

92 In this report, we describe the initial genomic epidemiology of SARS-CoV-2 recovered from 93 vaccinated healthcare professionals (HCPs) within a large healthcare network in New Jersey. 94 We specifically probe whether specific SARS-CoV-2 variants skew viral diversity indicative of 95 vaccine-induced selection; and compare against a random collection of SARS-CoV-2 recovered 96 from non-vaccinated individuals during the same time period. Although we find steep increases

97 in variants harboring E484K and N501Y among community samples, our early genomic
98 assessment does not indicate specific variant enrichment among post-vaccinated individuals.
99 We find that viral genomes among vaccinated individuals largely reflect the viral diversity among
100 non-vaccinated populations.

101

102 **RESULTS** 

## 103 COVID-19 post-vaccination surveillance program: demographic and clinical 104 characteristics of COVID-19 cases.

From December 2020 to April 2021, 23,697 of 37,500 HCPs (62%) received at least one dose of an mRNA vaccine, and 22,458 (59%, 22,458/37,500) received both vaccine doses. Among vaccinated employees, 12,878 (54%) received mRNA-1273 (Moderna) and 10,819 (46%) received BNT162b2 (Pfizer/BioNTech) mRNA COVID-19 vaccine. Of the 23,697 vaccinated (single and both doses) employees, our surveillance program detected 138 (0.58%, 138/23,697) COVID-19 cases, 105 of these were among employees who received only one dose and 33 (0.15%, 33/22,458) with both doses.

112

113 Among the 138 post-vaccinated COVID-19 cases, 74 were vaccinated with the Pfizer/BioNTech 114 vaccine and 64 were vaccinated with the Moderna preparation. Cases were reported from nine 115 hospitals. Demographic information was not available for 17 employees. Of the remaining 121 116 employees, most cases were white (68%) and female (74%) with a median age of 45 (ranging 117 from 19-77). Twenty-one employees (17%) were documented to have asymptomatic infection. 118 Of those that were symptomatic, five individuals requiring hospitalization received only one dose 119 and had recorded BMI of >25 (4 individuals with BMI >30) and four of these patients required 120 supplemental oxygen. The majority of the vaccine breakthroughs, 76% (105/138), occurred from 121 1-113 days after the initial dose with a median of 10 days, while 23% (33/138) occurred 4-104 122 days after the second dose with a median of 22 days.

123

## Screening of post-vaccinated SARS-CoV-2 infections indicate the rise in E484K and N501Y variants.

126 To further characterize the SARS-CoV-2 genotypes recovered from the post-vaccinated 127 individuals, we examined the spread of key mutations underlying VOCs (i.e., B.1.1.7) in New 128 Jersey using a high-throughput molecular beacon assay designed to screen for polymorphisms 129 N501Y/T and E484K/Q in the RBD region (10). Among 138 HCPs, 83 swabs were available for 130 rapid screening providing 76 genotypic results (60 from partial and 16 from fully vaccinated). 131 There were 3 and 6 viral samples with E484K and N501Y polymorphisms respectively (Figure 132 1). Among 16 fully vaccinated HCPs, we found 1 (6.3%) and 6 (38%) samples with E484K and 133 N501Y mutations, respectively.

To contextualize the prevalence of E484K and N501Y mutations among the non-vaccinated population, we randomly sampled 1,404 SARS-CoV-2 positive swabs (from a total of 3,000 positive COVID-19 swabs) from January 2021 to April 2021 within our hospital network. Overall, we detected 284 E484K/Q (284/1392, 20.4%, 12 samples failed in the E484 detection in comparison with N501Y) and 523 N501Y (523/1404, 37.3%) mutants (Figure 2). The prevalence of E484K/Q and N501Y from January to April, was 3.2% to 25.7% and 1.0% to 49.3%, respectively (Figure 2).

141

# SARS-CoV-2 from vaccinated individuals is diverse and does not indicate predominant genotypes or genetic characteristics.

To understand the population structure of SARS-CoV-2 post-vaccination, we first analyzed WGS data for 68 available SARS-CoV-2 isolates from 83 symptomatic COVID-19 cases included in this study. WGS failed for 15 samples due to high Ct values, suggestive of low viral burden. We specifically probed whether specific variants or mutations were overrepresented among SARS-CoV-2 recovered from vaccinated individuals. The 68 genomes were divided into

149 21 different Pangolin lineages with B.1.2 the most common (24/68, 35%) (Figure 3). We noted 150 distinct amino acid changes or deletions at 20 sites within the N-terminal domain (NTD) or 151 receptor-binding domain (RBD) regions of the spike protein. Mutations associated with antibody 152 evasion - L452R, T478K, E484K and S494P - were found in 3, 1, 3 and 2 genomes, 153 respectively. We did not detect any genomes with more than two of the four polymorphisms. 154 The N501Y mutation was found in 4% (3/68) of the genomes, and all belonged to the VOC 155 B.1.1.7 lineage. We recorded 3 viral samples harboring the E484K mutation, two belonged to 156 the B.1.526 lineage first identified in New York (11, 12) and one from the R.1 lineage. 157 Importantly, among the 9 individuals fully vaccinated (*i.e.*, ≥14 days post-second dose) we note 158 1 and 2 samples harboring E484K and N501Y polymorphisms, respectfully. There were no 159 samples from fully vaccinated HCPs with both E484K and N501Y.

160 To compare viral diversity from vaccinated and non-vaccinated individuals, we randomly 161 selected 281 SARS-CoV-2 samples recovered from non-vaccinated patients within the 162 Hackensack Meridian Health (HMH) network during the same time period for genomic 163 characterization by WGS (Figure 3). Among them, 38 different Pangolin lineages were 164 identified, including 18 lineages found in the vaccinated population. B.1.526 (n=33) and its sub-165 lineages (B.1.526.1, n=26, and B.1.526.2, n=15) were the most common (74/281, 26.3%), 166 followed by B.1.2 (35, 12.5%), B.1.1.7 (28, 10%) and B.1.575 (26, 9.3%). In addition, 5 P.1 167 (20J/501Y.V3) and 1 B.1.617.1 (Kappa) were found among the 281 samples. Mutations or 168 deletions were detected in 54 sites within the S protein RBD or NTD region, including 18 sites 169 found in the vaccinated samples. L452R, T478K/I, E484K/Q and S494P mutations were 170 identified in 32, 8, 40 and 29 genomes, respectively. Compared with the non-vaccinated 171 samples, we did not detect a significant increase in the frequency of any RBD/NTD mutations or 172 deletions among the vaccinated group (P > 0.05).

173

#### 174 **DISCUSSION**

Rapid expansion and contraction of SARS-CoV-2 populations coupled with increasing anti-CoV-2 immunity dynamics have contributed to pandemic phases accompanied by emergent genomic signatures (1, 13). Extensive polymorphisms in the spike protein have been documented, including N501Y and E484K mutations that are particularly concerning (14). In this report, we present early genomic analysis of SARS-CoV-2 from an ongoing post-vaccination COVID-19 surveillance program among healthcare workers in New Jersey.

181 We detected SARS-CoV-2 in 33 (0.15%) HCPs who were fully vaccinated, none of whom 182 required hospitalization. All symptomatic cases were noted among partially vaccinated HCPs 183 and were self-limiting with only 5 requiring hospitalization. Although our passive surveillance 184 system was intended to capture the HCP vaccinated population who self-reported symptoms or 185 who were exposed to a COVID-19 positive case, and not able to report true prevalence of 186 infections (i.e., mild or asymptomatic infections may be missed), our findings are consistent with 187 emerging reports of incident post-vaccination SARS-CoV-2 infections (15-18). A recent 188 multicenter prospective cohort study in England found vaccine effectiveness upwards of 85% 189 (19). Our results support high levels of protection afforded by vaccination, particularly among 190 recipients of both doses (9, 15, 20-24). The majority of cases in our study were among partially 191 vaccinated individuals, emphasizing the importance of personal protective measures, and 192 susceptibility to infection particularly until fully vaccinated (19, 24-27).

Steep transmission gradients reported locally and regionally have been partly attributed to VOCs, including B.1.1.7 in Europe and U.S., P.1 in Brazil, B.1.351 in South Africa, B.1.617.2 in India and B.1.526 in New York State (6-8, 11, 28). Although the pathogen characteristics attributable to the spread of these variants at the population-level are difficult to assess, mathematical modeling, genomic and experimental studies have demonstrated increased transmissibility and immune evasion properties, including reduced vaccine-induced antibody

neutralization *in vitro* (2, 3, 6, 14). Whether the rollout of vaccination would offer selective
advantage to VOCs is a critical question to determine.

201 A recent study from Washington State found that all SARS-CoV-2 vaccine breakthroughs 202 were VOCs. Of significance, those VOCs harboring immune evasion properties (B.1.351, 203 B.1.427, B.1.429, and P1) were enriched compared to B.1.1.7 lineages among vaccine 204 breakthrough cases when compared to cases in the general population (29). Other outbreaks 205 have been reported among vaccinated individuals implicating SARS-CoV-2 strains harboring 206 E484K, a noted immune evasion conferring polymorphism (20). A recent study where two VOCs 207 (B.1.351 and B.1.1.7) dominate the viral population, indicate reduced vaccine effectiveness 208 against both variants at specific time windows. Reduced effectiveness against B.1.351 at least 7 209 days after the second BNT162b2 dose, and against B.1.1.7 between 2 weeks after the first dose 210 and 6 days after the second dose were reported (24). However, among fully vaccinated HCPs 211 the VOC proportions between cases and controls were comparable, consistent with our 212 findings. These studies reinforce the need to fully vaccinate to achieve high levels of protection 213 afforded by vaccination (9).

214 In our study, despite an increasing trend in the proportion of N501Y and E484K variants in 215 the overall population (Figure 2), we do not find early evidence of genotypic enrichment of 216 polymorphisms within the NTD or RBD region of the spike protein gene among our fully 217 vaccinated HCPs. Although 44% of the strains recovered from fully vaccinated HCPs harbored 218 mutations of concern (6 N501Y and 1 E484K), they were similar in proportion to strains 219 circulating in the community during the same time period. Our WGS analysis suggests N501Y 220 harboring strains belong to the B1.1.7 lineage and the E484K mutants to the B.1.526 lineage, 221 both highly prevalent lineages in Northeastern US (12, 30). All N501Y mutants were detected 222 among fully vaccinated HCPs, half of which failed to generate WGS data due to higher Ct 223 values, a likely consequence of vaccination (31).

224 A recent report showed that B.1.1.7 upregulates key innate immune antagonists likely 225 increasing the transmission potential of this VOC (32). Interestingly, mRNA vaccines have 226 shown high levels of efficacy against B.1.1.7 infections (22). Overall, the genomic diversity of 227 SARS-CoV-2 recovered post-vaccination appears to proportionally represent the observed viral 228 diversity within the community. We acknowledge that our estimates may be skewed by under-229 sampling of asymptomatic infections among fully vaccinated individuals (33), and likely affected 230 by test seeking behavioral bias (24). However, our results are consistent with those from a large 231 nationwide surveillance program of COVID-19 vaccine breakthrough infections that found the 232 proportion of reported vaccine breakthrough infections attributed to VOCs to be similar to the 233 proportion of these variants circulating throughout the United States (27).

There is mounting evidence that currently available vaccines, including those used in our population, are highly effective against VOCs. The reports of VOC enrichment among postvaccinated individuals, despite small sample sizes, warrant surveillance. Our study findings are preliminary yet highlights the importance of full vaccination against circulating variants, including VOCs, and the need to continue SARS-CoV-2 genomic surveillance as vaccination coverage expands, pathogen evolves and immunity wanes.

240

#### 241 METHODS

#### 242 **Post-vaccination COVID-19 surveillance program.**

Since the first mRNA vaccines were administered in December 2020 among the 37,500 HMH employees, we initiated a symptoms-based surveillance program to identify and report the status of each vaccinated person in the Electronic Medical Record (EMR). This regularly updated list was cross-referenced daily against the results of all SARS-Cov-2 nucleic acid amplification tests (NAAT) in the HMH network. As a result, we were able to identify all vaccinated employees who tested positive for COVID-19 by NAAT after routine screening or

after reporting out sick. Non-team members who were vaccinated at our mass-vaccination site
or by physician report (and were thus in the HMH EMR) and subsequently tested positive for
COVID-19 by NAAT were also similarly identified. The study was approved by Hackensack
Meridian Health Institutional Review Board (IRB).

253

## 254 Whole genome sequencing and phylogenetic analysis

SARS-CoV-2 targeted assay libraries were prepared using the Molecular Loop Viral RNA Target Capture Kit (Molecular Loop) or QIAseq FX DNA Library UDI Kit (QIAGEN), in accordance with manufacturer's recommendations. Final libraries were quantified using fluorescent-based assays including PicoGreen (Life Technologies), Qubit Fluorometer (Invitrogen), and Fragment Analyzer (Advanced Analytics). Final libraries were sequenced on a NovaSeq 6000 sequencer (v1 chemistry) with 2x150bp.

261

For QIAseq libraries, read pairs that did not contain a single 19bp seed k-mer in common with the SARS-CoV-2 genome reference (NC\_045512.2) were discarded. Adapter sequences and low-quality bases (Q < 20) were trimmed from the 3' end of the remaining reads, using Cutadapt v2.10 (34). Sequences corresponding to the amplicon primers were also clipped from the 5' end of reads. Processed read pairs were then aligned to the SARS-CoV-2 reference genome, using BWA-MEM v0.7.17 (35) and only read pairs with at least one alignment spanning a minimum of 50 bp in the reference were kept.

269

For Molecular Loop libraries, the two 5bp UMIs located at the 5' end of each mate were first clipped and combined into a single UMI tag. Additional 25 bp, corresponding to the molecular inversion probes, were also clipped from the 5' end of each read. Next, read pairs that did not contain a single 19bp seed k-mer in common with the SARS-CoV-2 genome reference (NC 045512.2) were discarded and adapter sequences and low-guality bases (Q < 20) were

275 trimmed from the 3' end of the remaining reads, using Cutadapt v2.10 (34). Processed reads 276 pairs were then merged using NGmerge v0.2 (36), allowing for dovetailed alignments. The 277 resulting single end reads were mapped against the SARS-CoV-2 genome reference using 278 BWA-MEM v0.7.17 (35) and the resulting alignments filtered using the following criteria: 1) 279 reference span  $\geq$  50bp, 2) quality  $\geq$  60, and 3) maximum soft-clip length on either end  $\leq$  30bp. 280 Next, reads representing the same original molecule were identified based on their shared UMI 281 and alignment position and used to draw the molecule consensus sequence, taking into account 282 base quality scores. Molecule sequences were then realigned to the SARS-CoV-2 genome 283 reference using BWA-MEM v0.7.17 (35). Finally, genome sequences were determined either 284 by read (QIAseq) or molecule (Molecular Loop) alignment pileup consensus calling with a 285 minimum support of 5 reads/molecules.

286

287 The resulting SARS-CoV-2 viral genome sequences were characterized by Nextclade CLI (v1) 288 (https://clades.nextstrain.org/) to assign Nextstrain clades (37). SARS-CoV-2 lineages were 289 determined using Pangolin v3.1.3 (https://github.com/cov-lineages/pangolin) and GISAID clades 290 were determined based upon the clade-specific marker variants from https://www.gisaid.org 291 (38). The genomes were aligned using nextalign v1.0.0 (https://github.com/neherlab/nextalign), 292 using default setting. A maximum likelihood phylogenetic tree was constructed using IQ-TREE 293 v2.1.2 (39) with automatic model selection and 1000-bootstrap replicates. The resulting tree 294 was annotated using ITOL v6 (40).

295

#### 296 **Population sampling and screening of SARS-CoV-2**

297 SARS-CoV-2 positive swabs collected from seven HMH network hospitals were shipped to CDI 298 on a weekly basis and stored at -80°C. 1,404 swabs collected during the same time frame as 299 the vaccinated samples were randomly selected and subjected to a molecular beacon-based 300 real-time asymmetric PCR and melting curve analysis to identify the SARS-CoV-2 E484K/Q and

301 N501Y mutations, as previously described (10). In brief, 50 µl aliquots of SARS-CoV-2 swab 302 specimens were treated by proteinase K and heated at 95°C for 5 min. 5ul of heat inactivated 303 sample was used as template for the asymmetric RT-PCR testing on a Mic Real Time PCR 304 Cycler (Bio Molecular Systems, software micPCRv2.8.13). Based on the different melting 305 profiles (Tm) of E484 and N501 molecular beacons in each sample, the E484K and N501Y 306 mutations were determined.

307

## **308** Statistical analysis

Fisher's exact or chi-square tests, as appropriate, were used to examine whether the spike protein NTD/RBD mutations were enriched in the vaccinated HCPs (n=68) in comparison with the non-vaccinated patients (n=281). SPSS, version 17.0 (IBM Corp., Armonk, NY) was used for statistical analyses and two-tailed P values  $\leq 0.05$  were considered statistically significant.

313

## **Data availability**

The SARS-CoV-2 genomes sequenced in this study were deposited in GISAID (www.gisaid.org). Sequences can be accessed by searching records from both the originating lab at Hackensack Medical Center and the submitting lab at the New York Genome Center.

319	FIGURE 1. Clinical characteristics of 83 COVID-19 vaccinated HCPs and their SARS-CoV-2 S
320	protein E484 and N501 genotypes. The samples were ordered by the time of diagnosis, with the
321	the first case detection week denoted as "0".
322	
323	
324	
325	
326	
327	FIGURE 2. Prevalence of E484K/Q and N501Y mutants among SARS-Cov-2 samples from
328	non-vaccinated individuals from January to April 2021.
329	
330	
331	
332	
333	FIGURE 3. Maximum Likelihood Phylogenetic tree of 349 SARS-CoV-2 genomes isolated from
334	vaccinated and non-vaccinated populations. The tree is rooted to the SARS-CoV-2 Wuhan-Hu-1
335	reference genome (NC_045512.2). The scale represents 0.0001 nucleotide substitutions per
336	site. The vaccination conditions are color coded at the tree tips: purple, black and white tips
337	denote single-dose, double-dose vaccine and non-vaccination, respectively. The SARS-CoV-2
338	Pangolin lineage is illustrated as a color bar and the S protein NTD/RBD mutations are shown
339	as a heatmap on the right panel.

## 341 References:

343	1.	Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. 2020. Projecting the
344		transmission dynamics of SARS-CoV-2 through the postpandemic period. Science
345		368:860-868.
346	2.	Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, Reichmuth
347		ML, Bowen JE, Walls AC, Corti D, Bloom JD, Veesler D, Mateo D, Hernando A, Comas
348		I, Candelas FG, Seq C-Sc, Stadler T, Neher RA. 2021. Spread of a SARS-CoV-2 variant
349		through Europe in the summer of 2020. Nature doi:10.1038/s41586-021-03677-y.
350	3.	Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ,
351		Bloom JD. 2021. Prospective mapping of viral mutations that escape antibodies used to
352		treat COVID-19. Science 371:850-854.
353	4.	Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD.
354		2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding
355		domain that affect recognition by polyclonal human plasma antibodies. Cell Host
356		Microbe 29:463-476 e6.
357	5.	Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L, Geneva Centre for
358		Emerging Viral D. 2021. Novel SARS-CoV-2 variants: the pandemics within the
359		pandemic. Clin Microbiol Infect doi:10.1016/j.cmi.2021.05.022.
360	6.	Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon
361		DJ, Dabrera G, O'Toole A, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani
362		CV, Boyd O, Loman NJ, McCrone JT, Goncalves S, Jorgensen D, Myers R, Hill V,
363		Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP, consortium C-GU,

364		Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM. 2021.
365		Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593:266-
366		269.
367	7.	Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D,
368		Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A,
369		Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A,
370		Hardie D, Marais G, Hsiao NY, Korsman S, Davies MA, Tyers L, Mudau I, York D,
371		Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik
372		A, Wibmer CK, Sewell BT, Lourenco J, Alcantara LCJ, Kosakovsky Pond SL, Weaver S,
373		Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. 2021. Detection of a
374		SARS-CoV-2 variant of concern in South Africa. Nature 592:438-443.
375	8.	Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, Crispim MAE,
376		Sales FCS, Hawryluk I, McCrone JT, Hulswit RJG, Franco LAM, Ramundo MS, de
377		Jesus JG, Andrade PS, Coletti TM, Ferreira GM, Silva CAM, Manuli ER, Pereira RHM,
378		Peixoto PS, Kraemer MUG, Gaburo N, Jr., Camilo CDC, Hoeltgebaum H, Souza WM,
379		Rocha EC, de Souza LM, de Pinho MC, Araujo LJT, Malta FSV, de Lima AB, Silva
380		JDP, Zauli DAG, Ferreira ACS, Schnekenberg RP, Laydon DJ, Walker PGT, Schluter
381		HM, Dos Santos ALP, Vidal MS, Del Caro VS, Filho RMF, Dos Santos HM, Aguiar RS,
382		Proenca-Modena JL, Nelson B, Hay JA, Monod M, Miscouridou X, et al. 2021.
383		Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science
384		372:815-821.
385	9.	Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik
386		A, Jansen KU, Sahin U, Xie X, Dormitzer PR, Shi PY. 2021. BNT162b2-elicited

387		neutralization of B.1.617 and other SARS-CoV-2 variants. Nature doi:10.1038/s41586-
388		021-03693-у.
389	10.	Zhao Y, Lee A, Composto K, Cunningham MH, Mediavilla JR, Fennessey S, Corvelo A,

- 390 Chow KF, Zody M, Chen L, Kreiswirth BN, Perlin DS. 2021. A novel diagnostic test to
- 391 screen SARS-CoV-2 variants containing E484K and N501Y mutations. Emerg Microbes
   392 Infect 10:994-997.
- 393 11. Annavajhala MK, Mohri H, Zucker JE, Sheng Z, Wang P, Gomez-Simmonds A, Ho DD,
- 394 Uhlemann AC. 2021. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in

395 New York. medRxiv doi:10.1101/2021.02.23.21252259.

- 396 12. Thompson CN, Hughes S, Ngai S, Baumgartner J, Wang JC, McGibbon E, Devinney K,
- 397 Luoma E, Bertolino D, Hwang C, Kepler K, Del Castillo C, Hopkins M, Lee H, DeVito
- 398 AK, Rakeman JL, PhD, Fine AD. 2021. Rapid Emergence and Epidemiologic
- 399 Characteristics of the SARS-CoV-2 B.1.526 Variant New York City, New York,

400 January 1-April 5, 2021. MMWR Morb Mortal Wkly Rep 70:712-716.

- 401 13. Cobey S, Larremore DB, Grad YH, Lipsitch M. 2021. Concerns about SARS-CoV-2
- 402 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol 21:330-403 335.
- 404 14. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD,
- 405 Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L,
- 406 Sheng Z, Huang Y, Ho DD. 2021. Antibody resistance of SARS-CoV-2 variants B.1.351
- 407 and B.1.1.7. Nature 593:130-135.
- 408 15. Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, Steiner J, Schechter-
- 409 Perkins EM, Duffy E, Ragan EJ, Taylor BP, Schaeffer B, Miller N, Davidoff R, Hanage

- 410 WP, Connor J, Pierre C, Jacobson KR. 2021. COVID-19 vaccine impact on rates of
- 411 SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at
- 412 an urban academic medical center: a prospective cohort study. medRxiv
- 413 doi:10.1101/2021.03.30.21254655.
- 414 16. Daniel W, Nivet M, Warner J, Podolsky DK. 2021. Early Evidence of the Effect of
- 415 SARS-CoV-2 Vaccine at One Medical Center. N Engl J Med 384:1962-1963.
- 416 17. Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, Abeles SR,
- 417 Torriani FJ. 2021. SARS-CoV-2 Infection after Vaccination in Health Care Workers in
- 418 California. N Engl J Med 384:1774-1775.
- 419 18. Teran RA, Walblay KA, Shane EL, Xydis S, Gretsch S, Gagner A, Samala U, Choi H,
- 420 Zelinski C, Black SR. 2021. Postvaccination SARS-CoV-2 Infections Among Skilled
- 421 Nursing Facility Residents and Staff Members Chicago, Illinois, December 2020-March
- 422 2021. MMWR Morb Mortal Wkly Rep 70:632-638.
- 423 19. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J,
- 424 Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS,
- 425 Ramsay M, Lopez-Bernal J, Hopkins S, Group SS. 2021. COVID-19 vaccine coverage in
- 426 health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against
- 427 infection (SIREN): a prospective, multicentre, cohort study. Lancet 397:1725-1735.
- 428 20. Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, Tobias J, Lunn S,
- 429 Miller T, Thoroughman D, Spicer KB. 2021. COVID-19 Outbreak Associated with a
- 430 SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination
- 431 Program Kentucky, March 2021. MMWR Morb Mortal Wkly Rep 70:639-643.

432	21.	Dagan N. Barda N	. Kepten F	. Miron O	. Perchik S	. Katz MA	Hernan MA.	Lipsitch M.
154	41.	Dugun 1, Duruu 1	, nopton L	, minon o	, I CICHING D	, <b>I L U U U U U</b>	, <b>110</b> 111011 1 <b>1</b> 11 1 <b>,</b>	Lipsicen in,

- 433 Reis B, Balicer RD. 2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
- 434 Vaccination Setting. N Engl J Med 384:1412-1423.
- 435 22. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M,
- 436 Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. 2021.
- 437 Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections
- 438 and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination
- 439 campaign in Israel: an observational study using national surveillance data. Lancet
- 440 397:1819-1829.
- 441 23. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. 2021.
- 442 Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and
- 443 Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA
- 444 doi:10.1001/jama.2021.7152.
- 445 24. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky
- 446 M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L,
- 447 Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni
- 448 Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A. 2021. Evidence
- for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-
- 450 mRNA-vaccinated individuals. Nat Med doi:10.1038/s41591-021-01413-7.
- 451 25. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for C-V. 2021.
- 452 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351
- 453 Variants. N Engl J Med doi:10.1056/NEJMc2104974.

454	26.	Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I,
455		Twig G, Cohen D, Muhsen K. 2021. The effectiveness of the TWO-DOSE BNT162b2
456		vaccine: analysis of real-world data. Clin Infect Dis doi:10.1093/cid/ciab438.
457	27.	Team CC-VBCI. 2021. COVID-19 Vaccine Breakthrough Infections Reported to CDC -
458		United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 70:792-793.
459	28.	Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, Mellan TA,
460		du Plessis L, Pereira RHM, Sales FCS, Manuli ER, Theze J, Almeida L, Menezes MT,
461		Voloch CM, Fumagalli MJ, Coletti TM, da Silva CAM, Ramundo MS, Amorim MR,
462		Hoeltgebaum HH, Mishra S, Gill MS, Carvalho LM, Buss LF, Prete CA, Jr., Ashworth J,
463		Nakaya HI, Peixoto PS, Brady OJ, Nicholls SM, Tanuri A, Rossi AD, Braga CKV,
464		Gerber AL, de CGAP, Gaburo N, Jr., Alencar CS, Ferreira ACS, Lima CX, Levi JE,
465		Granato C, Ferreira GM, Francisco RS, Jr., Granja F, Garcia MT, Moretti ML, Perroud
466		MW, Jr., Castineiras T, Lazari CS, et al. 2020. Evolution and epidemic spread of SARS-
467		CoV-2 in Brazil. Science doi:10.1126/science.abd2161.
468	29.	McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, Schippers A, Strand
469		K, Whimbey E, Mani NS, Zelikoff AJ, Makarewicz VA, Brown ER, Mohamed Bakhash
470		SA, Baker NR, Castor J, Livingston RJ, Huang M-L, Jerome KR, Greninger AL,
471		Roychoudhury P. 2021. Variants of concern are overrepresented among post-vaccination
472		breakthrough infections of SARS-CoV-2 in Washington State. medRxiv
473		doi:10.1101/2021.05.23.21257679:2021.05.23.21257679.
474	30.	West AP, Wertheim JO, Wang JC, Vasylyeva TI, Havens JL, Chowdhury MA, Gonzalez
475		E, Fang CE, Di Lonardo SS, Hughes S, Rakeman JL, Lee HH, Barnes CO,
476		Gnanapragasam PNP, Yang Z, Gaebler C, Caskey M, Nussenzweig MC, Keeffe JR,

- 477 Bjorkman PJ. 2021. Detection and characterization of the SARS-CoV-2 lineage B.1.526
  478 in New York. bioRxiv doi:10.1101/2021.02.14.431043.
- 479 31. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler
- 480 V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R. 2021. Initial report of
- 481 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat
- 482 Med 27:790-792.
- 483 32. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J,
- 484 Whelan MVX, Ummadi M, Rojc A, Turner J, Obernier K, Braberg H, Soucheray M,
- 485 Richards A, Chen KH, Harjai B, Memon D, Hosmillo M, Hiatt J, Jahun A, Goodfellow
- 486 IG, Fabius JM, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Swaney DL,
- 487 Garcia-Sastre A, Jolly C, Towers GJ, Krogan NJ. 2021. Evolution of enhanced innate

488 immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv

- 489 doi:10.1101/2021.06.06.446826.
- 490 33. Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, Mina MJ.
- 491 2021. Estimating epidemiologic dynamics from cross-sectional viral load distributions.
- 492 Science doi:10.1126/science.abh0635.
- 493 34. Kechin A, Boyarskikh U, Kel A, Filipenko M. 2017. cutPrimers: A New Tool for

494 Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing. J
495 Comput Biol 24:1138-1143.

- 496 35. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler
  497 transform. Bioinformatics 25:1754-60.
- 498 36. Gaspar JM. 2018. NGmerge: merging paired-end reads via novel empirically-derived
  499 models of sequencing errors. BMC Bioinformatics 19:536.

500	37.	Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P,	
-----	-----	--	--

- 501 Bedford T, Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution.
- 502 Bioinformatics 34:4121-4123.
- 503 38. Elbe S, Buckland-Merrett G. 2017. Data, disease and diplomacy: GISAID's innovative
- 504 contribution to global health. Glob Chall 1:33-46.
- 505 39. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: a fast and
- 506 effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol
- 507 Evol 32:268-74.
- 508 40. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new
- 509 developments. Nucleic Acids Res 47:W256-W259.





Lineage B.1.1.434 B.1.1.7 B.1.2 B.1.234 B.1.243 B.1.429 B.1.526 B.1.526.1 B.1.526.2 B.1.575 B.1.596 B.1.617.1 P.1 R.1 Other

## **NTD/RBD** mutation





